Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the underlying causes of ALS has made it difficult to target upstream biological mechanisms of disease, and therapeutic interventions are usually...

Descripción completa

Detalles Bibliográficos
Autores principales: Benatar, Michael, Wuu, Joanne, Andersen, Peter M., Bucelli, Robert C., Andrews, Jinsy A., Otto, Markus, Farahany, Nita A., Harrington, Elizabeth A., Chen, Weiping, Mitchell, Adele A., Ferguson, Toby, Chew, Sheena, Gedney, Liz, Oakley, Sue, Heo, Jeong, Chary, Sowmya, Fanning, Laura, Graham, Danielle, Sun, Peng, Liu, Yingying, Wong, Janice, Fradette, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587202/
https://www.ncbi.nlm.nih.gov/pubmed/35585374
http://dx.doi.org/10.1007/s13311-022-01237-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587202/
https://www.ncbi.nlm.nih.gov/pubmed/35585374
http://dx.doi.org/10.1007/s13311-022-01237-4

Ejemplares similares